Recent Advances in Anti-Infective Drug Discovery · مجلد 21 (3) · 205-219
Japanese encephalitis (JE) remains a major public health concern, especially in Asia and the Western Pacific, where more than 3 billion people are at risk. Despite advances in vaccine development, challenges such as viral strain diversity, limited crossprotection, and access barriers persist. JE directly impacts economic development because disease patterns are influenced by factors such as healthcare infrastructure, surveillance, vaccine availability, and agricultural trends across low-, middle-, upper-, and high-income countries. Current vaccines primarily target genotype III strains, but genotype I has become dominant in many endemic areas, raising concerns about vaccine efficacy. Furthermore, the need for booster doses, cold chain storage requirements, and high production costs all contribute to limited immunization coverage. Recent innovations, including thermostable formulations, multivalent vaccines, and mRNA-based candidates, offer promising solutions for JE prevention. Global initiatives by organizations such as WHO, GAVI, and PATH have played a critical role in increasing vaccine accessibility, yet gaps remain in achieving universal coverage. This review addresses the progress, challenges, and emerging strategies in JE vaccine development, emphasizing the importance of innovative approaches to ensure global protection against this life-threatening disease.
Japanese encephalitisJE vaccinevaccine developmentgenotype I
We present a case of palmoplantar pustulosis (PPP) occurring as a paradoxical reaction to secukinumab in a 26-year-old man with long-standing Hurley stage III hidradenitis suppurativa (HS). Following the fifth dose of secukinumab, the patient developed painful, erythematous, scaly plaques with sterile pustules localized to the palms and soles. The clinical presentation was consistent with PPP, and the lesions improved after discontinuation of secukinumab and initiation of adalimumab.
paradoxical drug reactionsecukinumabpalmoplantar pustulosishidradenitis suppurativa
Background: Human papillomavirus (HPV) is a leading cause of cervical cancer and other HPV-related cancers globally. Vaccination against HPV has proven to be a pivotal intervention in reducing the burden of these diseases. However, questions remain regarding long-term efficacy, dosing strategies, and real-world outcomes of HPV vaccines. Objective: We aim to synthesise evidence from randomised controlled trials and long-term follow-up studies on the efficacy, immunogenicity, safety, and real-world impact of HPV vaccines. Methodology: A comprehensive search was conducted in PubMed, Cochrane Library, Embase, Scopus, and Web of Science for studies published in English from 2019 to 2024. Eligible studies included randomised controlled trials and long-term follow-up analyses focusing on HPV vaccine efficacy, dosing regimens, and population-specific outcomes. Data were extracted and synthesised narratively, with findings organised into five thematic areas. Results: Seventeen studies met the inclusion criteria. Findings confirm the high efficacy of HPV vaccines in preventing HPV-related cancers and precancers, with durable immunogenicity observed up to 12 years post-vaccination. Evidence supports the potential of single-dose regimens, which could improve accessibility in resource-limited settings. Real-world data demonstrated significant reductions in HPV-related diseases across diverse populations, reinforcing the global impact of HPV vaccination programs. Conclusion: This review highlights the critical role of HPV vaccines in reducing the burden of HPV-related cancers, with robust efficacy, long-term protection, and favourable safety profiles. The findings underscore the need for continued research into optimised vaccination strategies and the expansion of global vaccination efforts.
HPV vaccinationhuman papillomaviruscervical cancer preventionHPV-associated cancers
BACKGROUND: Direct-Acting Antivirals (DAAs) are effective in 95% of patients, but concerns about potential cardiotoxicity and decreased Warfarin Sensitivity (WS) need further investigation. The study aimed to evaluate the safety and effectiveness of sofosbuvir-based therapy in patients with significant heart diseases, considering potential drug interactions and their impact on cardiac function. METHODS: The study involved 100 patients with HCV genotype 4, including 40 with ischemic heart disease, 20 with prosthetic valve replacement, 20 with NYHA class I‒II heart failure, and 20 with systemic hypertension. All received sofosbuvir-based antiviral therapy and underwent routine laboratory tests, N-Terminal B-type Natriuretic Peptide (NT-Pro BNP), abdominal ultrasound, and echocardiography at baseline and three months post-treatment. RESULTS: Ninety-six patients achieved SVR, resulting in improved cardiac ejection fraction (EF) from 53.2 ± 8.8% to 56.2 ± 6.9% (p = 0.000) and reduced left atrial volume (LAV) from 43.2 ± 4.2 to 41.7 ± 3.9 mm (p = 0.008). Liver stiffness also improved (p = 0.013), and no disabling symptoms were reported. MAPSE increased from 8.4 ± 2.4 mm to 9.5 ± 2.5 mm, and interventricular septum thickness (IVT) decreased from 12.5 ± 1.8 mm to 10.9 ± 1.3 mm (p = 0.001 and P = 0.000, respectively). The warfarin dose needed to be increased to optimize INR after SVR, but this adjustment did not affect WS (p = 0.16). CONCLUSION: Sofosbuvir-based antiviral therapy was well tolerated and demonstrated a reassuring cardiac safety profile in HCV patients with pre-existing heart disease, with no major arrhythmias or adverse cardiac events observed during or after therapy.
The continuous progression of cancerous severity due to the interaction of physical (ultraviolet radiation), chemical (smoking, mycotoxins, and heavy metals), and biological (microbial populations) carcinogens inspired scientists to develop a correlation between active therapeutic agents and cancer proliferation. This review highlights the molecular mechanism by which lycopene imparts its anticancerous role, focusing on clinical and animal trials to validate its effectiveness. The antioxidant profile of lycopene promotes anticancerous properties that reduce cancer prevalence by activating cell signaling pathways and gene expression (involved in cancer cell proliferation). Lycopene's anti-inflammatory properties suppresses the tumor growth and development-promoting pathways, such as the PI3K/Akt/mTOR pathway. The anticancer property of lycopene is also evidenced by its inhibitory potential of the Wnt/β-catenin signaling pathway that is involved in cancer cell modulation and propagation. Lycopene also suppresses and neutralizes oxidative stress and reactive oxygen species (ROS)-induced DNA damage, preventing gene mutation. Inflammation-induced cell death is mitigated by lycopene's anti-inflammatory potential that lowers the expression of interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Several clinical and randomized control trials have revealed the effect of lycopene supplementation in the management of cancer, including breast cancer, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, skin cancer, oral cancer, liver cancer, gastric cancer, and kidney cancer, by lessening prostate-specific antigen (PSA) levels. These studies also accentuate certain limitations that need further trials to evaluate the long-term consequences of lycopene supplementations and their specific effective dose.
The aura of the 21st century has been transformed due to a revolutionized health care system and modern industrial applications. However, human health and well-being are still a global challenge, affected by various metabolic and pathological morbidities, causing millions of mortalities. Cancer is one of the leading causes of fatalities globally, occurring due to pathogens, dietary factors, environmental toxins, occupational chemical exposure, and radiation. These factors lead to oxidative stress (OS), inflammation, DNA damage, epigenetic and genetic mutations, cell proliferation, tumorigenesis, and other chronic metabolic disorders such as diabetes mellitus, cardiovascular disorders, gastrointestinal problems, and hepato-renal syndrome. Among various types of cancers, lung cancer is leading them all, followed by breast and colorectal cancer (CRC). The oncogenesis includes activation of pro-inflammatory markers (IL-6, IL-1β, TNF-α), resulting in overexpression of oncogenes, downregulation of tumor suppressor genes (TSGs) like p53, pRb, APC, PTEN, suppression of antioxidant enzymes (GSH, CAT, SOD), and activation of signaling pathways (PI3K/Akt/mTOR/NF-κB, Ras/MAPK). However, plant-based herbal medicine is a valuable, affordable, and available management approach to reduce the risks of oncogenesis and other ailments. The bioactive compounds of these herbs make them an effective way to reduce inflammation, cancer, and the risk of other health problems. Eugenol (Eug), a volatile phenolic bioactive compound with a formula of C10H12O2, has been reported to have anticancer, antidiabetic, cardio- and pulmonary protective roles. Moreover, it can improve gut health and prevent neurodegenerative disorders. According to WHO, the safe dose of eugenol is 2.5 mg/kg for consumption. The current review focuses on the anticancer potential and other pharmacological aspects of eugenol through possible mechanisms.
Lipids in Health and Disease · مجلد 24 (1) · 109-109
BACKGROUND: Hypertriglyceridemia is an independent risk factor for cardiovascular diseases. In previous trials, apolipoprotein C-III (APOC3) inhibition through the antisense oligonucleotides volanesorsen, olezarsen, and plozasiran reduced triglyceride levels. However, the three medications' safety and efficacy have yet to be compared. METHODS: A network meta-analysis was performed to compare multiple doses of the three medications to each other through the placebo. Randomized controlled trials (RCTs) were retrieved by searching PubMed, EMBASE, Web of Science, SCOPUS, and Cochrane until November 22nd, 2024. The mean difference (MD) and 95% confidence interval (CI) were used for continuous outcomes. The risk ratio (RR) and 95% CI were used for dichotomous outcomes. RESULTS: Ten RCTs with a total of 1,129 patients were included. volanesorsen 300 mg once weekly showed the most significant percent reduction in triglyceride levels (MD = -91.0%, 95% CI: (-109.2%; -72.8%); P < 0.01). Only plozasiran once monthly, regardless of the dose, showed a non-significant percent reduction in triglycerides. This finding should be taken cautiously as the data were derived from a phase 1 trial with a small sample size. All the regimens significantly reduced APOC3 levels compared to placebo, with plozasiran 100 mg monthly and volanesorsen 300 mg once weekly showing the most significant reduction (MD range: -92.8% to -88.5%; P < 0.01). None of the treatments showed a statistically significant difference in overall adverse events rate compared to the placebo. CONCLUSION: APOC3 antisense oligonucleotide inhibitors effectively reduced triglyceride and APOC3 levels in hypertriglyceridemia with an acceptable safety profile. However, the results should be interpreted cautiously due to the small sample size. Further research is needed to confirm the beneficial effects of APOC3 inhibitors and show strong evidence of the impact of each regimen.
This study demonstrates the green synthesis, characterization, and biomedical applications of zinc oxide nanoparticles (ZnONPs) using Zingiber officinale (Z. officinale) (ginger) peel extract. Green synthesis offers advantages over conventional methods, including environmental friendliness, cost-effectiveness, and enhanced biocompatibility. Ultraviolet-Visible (UV-Vis) spectroscopy confirmed ZnONPs formation with a peak at 364 nm. Fourier-Transform Infrared (FTIR) spectroscopy analysis revealed characteristic peaks indicating functional groups involved in nanoparticle formation. Scanning Electron Microscope (SEM) analysis showed spherical/agglomerated nanoparticles, and Energy-Dispersive X-ray Spectroscopy (EDS) confirmed 77.7% zinc oxide by mass%. The X-ray Diffraction (XRD) indicated an average particle size of 24.67 nm with distinct crystal orientations. Phytochemical analysis detected alkaloids, saponins, and steroids in the extract. Optimal synthesis occurred at 50-60°C and pH 10, yielding stable ZnONPs. The ZnONPs exhibited significant antibacterial activity against Staphylococcus aureus (S. aureus), Bacillus subtilis (B. subtilis), Bacillus cereus (B. cereus), Escherichia coli (E.coli), Zymomonas mobilis (Z. mobilis), and Pseudomonas aeruginosa (P. aeruginosa), as well as antifungal activity against Candida albicans (C. albicans). The in vitro cytotoxicity study on M.D. Anderson - Metastatic Breast - 231 (MDA-MB-231) breast cancer cells showed a dose-dependent reduction in cell viability [Half-maximal Inhibitory Concentration (IC50) = 82.13 µg/mL] with notable morphological changes at higher concentrations. The ZnONPs synthesized from ginger peel extract are innovative, environmentally friendly, and economical. Our findings show that biologically generated ZnONPs are effective antibacterial and antifungal agents against several pathogens. This research uniquely demonstrates the potential of ginger peel, a commonly discarded agro-waste, as a sustainable source for ZnONPs synthesis, highlighting its biotechnological and medicinal applications. The novelty of this study lies in the green synthesis approach using ginger peel and the comprehensive evaluation of its antimicrobial and anticancer properties. Further in-depth studies and optimization are needed to validate their therapeutic efficacy and safety.
Archives of Physiology and Biochemistry · مجلد 131 (6) · 1045-1060
BACKGROUND: Gastric ulcer is commonly affected by several causes, including stress. This work examined the gastroprotective effects of ellagic acid (EA), in stress-induced gastric ulcers in Wistar rats. METHODS: Forty male Wistar rats were categorized into five groups: a normal control group, a stress-induced ulcer group, and three groups receiving EA treatment (5 mg, 10 mg, and 20 mg). Gastric ulcers were elicited using a water immersion stress model. Macroscopic and histological assessments, together with biochemical immunohistochemical studies were performed. RESULTS: EA therapy markedly decreased ulcer scores and indices in a dose-dependent manner. EA decreased TNF-α, IL-1β and MDA and augmented PGE1 and GSH. Histopathological assessments verified the results. The immunohistochemical analysis revealed increased Nrf2 and HO-1 levels and decreased NF-κB and COX-2 levels in the EA-treated groups. CONCLUSION: EA demonstrates gastroprotective properties against stress-induced gastric ulcers via its anti-inflammatory and antioxidant mechanisms in a dose-dependent manner.
Journal of the World Aquaculture Society · مجلد 56 (2)
Abstract Maintaining a healthy intestine is essential for growth and host defense mechanisms of farmed fish, particularly those densely stocked. In this context, maintaining a healthy intestinal microbiota for proper digestion, absorption, and integrity of the mucosa is of utmost importance. Nano‐form (SeNPs)‐enriched‐Pediastrum boryanum (Turpin) exhibits antimicrobial, antioxidant, and antitumor properties. Therefore, SeNPs are valuable nutritional supplements for farmed aquatic animals. Algogenic Se nanoparticles (SeNPs, 79.26 nm) were synthesized from the green microalga Pediastrum boryanum. A Nile tilapia (Oreochromis niloticus) basal diet was blended with 0.75 or 1.5 mg/kg dry feed of the SeNPs for and fed for 8 weeks. Comprehensive arrays of intestinal biomarker‐related parameters were investigated. Supplementation with SeNPs, particularly at a 1.5 mg/kg diet, improved growth performance, amylase and lipase activity, serotonin metabolite level, and intestinal morphometry. In addition, SeNPs supplementation suppressed serotonin levels. SeNPs at a 1.5 mg/kg diet were observed to be the optimal dose, as they showed better results concerning the increase in beneficial microbes and decrease in pathogenic microbes, demonstrating the potential role of SeNPs in growth improvement and enhanced intestinal functions. The sum of our data underscores the benefits of supplementing Nile tilapia feed with SeNPs to promote the growth and profitability of aquaculture.
Frontiers in Pharmacology · مجلد 16 · 1622018-1622018
Introduction: Repetitive traumatic brain injury (RTBI) represents a cumulative neurological insult associated with progressive neurodegeneration and limited therapeutic options. In this study, we uniquely evaluate the neuroprotective potential of mesenchymal stem cell (MSC)-derived exosomes in a rat model of RTBI, an area scarcely explored. Methods: RTBI was induced via a controlled mechanical impact to the skull once every day for 5 days. MSC-derived exosomes were administered 24 h after the final insult in two paradigms: a single dose (MSC-Ex1) with 2 weeks of follow-up, and a dual dose (MSC-Ex2) given 1 week apart, with sacrifice 1 week later. Rats were assigned to four groups: control, RTBI, RTBI + MSC-Ex1, and RTBI + MSC-Ex2. Results: MSC-derived exosome regimens comparably restored cognitive performance in the Novel Object Recognition and Y-maze tests. While both treatment paradigms preserved cortical histoarchitecture, the double-dose regimen led to a more pronounced restoration compared to the moderate tissue recovery observed in the single-dose group. Crucially, this work identifies parthanatos inhibition as a novel mechanistic axis for MSC-derived exosomes-mediated neuroprotection. MSC-derived exosomes attenuated excitotoxicity and oxidative stress, quelling the parthanatos cascade by suppressing PARP1, PAR polymers, nuclear AIF and MIF, as well as calpain, key executors of this caspase-independent cell death pathway. Additionally, MSC-derived exosomes normalized cyclophilin B and Hsp70 levels, suggesting their compensatory role in modulating the endogenous stress response. Conclusion: Overall, these findings demonstrate that MSC-derived exosomes counteract RTBI-induced neurodegeneration through multifaceted mechanisms, with parthanatos suppression at the core. Importantly, the dual-dosing regimen conferred no significant benefit over the single dose, highlighting the therapeutic promise of early intervention. This study positions MSC-derived exosomes as a novel, cell-free therapy capable of intercepting RTBI-induced neuropathology by targeting an under recognized form of programmed cell death.
Environmental Pollutants and Bioavailability · مجلد 37 (1)
This study assessed the effect of thiamethoxam on the Nile tilapia (Oreochromis niloticus) under subacute and chronic exposure. The study focused on biochemical markers, genetic damage, pesticide residue levels in fish flesh, and histopathological changes in fish exposed to different concentrations of thiamethoxam (25, 50) for 30 days and (100, 250 mg/L) for 4 days. The study found that prolonged exposure to high doses of thiamethoxam (50 mg/L for 30 days) had significant negative effects on fish health. This exposure led to increased levels of urea and ALT in the blood, indicating potential damage to the kidneys and liver. Additionally, thiamethoxam caused oxidative stress, as evidenced by elevated levels of MDA and upregulated TLR2 gene expression. Thiamethoxam also negatively impacted the fish’s antioxidant defense system. It significantly reduced the expression of key antioxidant genes like ghrelin and catalase, particularly at 250 mg/L for 4 days. The total antioxidant capacity (TAC) and superoxide dismutase (SOD) levels remained relatively stable, except for slight decreases at the highest dose. Thiamethoxam residues were detected in the muscle tissue of fish, with the highest levels found in the 250 mg/L for 4 days. Histological examination revealed severe degenerative changes in the gills and liver tissues of the fish exposed to thiamethoxam, with the severity of the damage increasing with the concentration of the pesticide. In conclusion, cautions must be taken when we use neonicotinoids due to its negative feedback impact on Nile Tilapia fish health and consequently affect humans as a final consumer.
Cancer is emerging as a leading cause of death globally. Considering the disease burden, scientists are working to develop various strategies by exploring natural sources for cancer treatment. The use of olive oil (OO) and its phytochemicals, specifically oleuropein and hydroxytyrosol (HT), as a remedy against various types of cancer is gaining attention among scientists and researchers. The current review aimed to highlight the antioxidant potential and summarize the various pathways and markers involved in the prevention and treatment of different human cancers. The databases, including Google Scholar, PubMed, and Web of Science, were searched to collect relevant data. The studies showed that some markers are specifically linked to particular types of cancers (such as 27-OHC, ATF-2, TNFRSF10B, HER2, and MET, which are linked to breast cancer; iNOS and NO, which are linked to thyroid cancer; GLUT1 and GLUT4, HIF-1α, MCT4, PKM2, PD-1, PD-L1, and CTLA-4, which are linked to colorectal cancer). Olive oil is involved in the management of these markers to prevent and/or treat all types of cancers by upregulating tumor suppressor genes, downregulating oncogenes, and modulating different pathways (PI3K/AKT/mTOR, Wnt/β-catenin, and MAPK). Taken together, it can be concluded that olive oil and its components have prominent potential to cure cancers in the human body. However, further investigations can be carried out to suggest the lethal doses of olive oils as a whole and its phytochemicals individually for the treatment of cancer.
Resistomycin, a microbial secondary metabolite, exhibits promising anticancer potential, yet its mechanism of action remains poorly understood. Here, we combined computational and biological assays to investigate its activity against Topoisomerase II (Topo II). Molecular docking predicted strong binding within the Topo II–DNA complex (–20.76 kcal/mol), while 200 ns molecular dynamics simulations confirmed a stable intercalation mode. Energy decomposition revealed van der Waals interactions as the dominant stabilizing force, with persistent hydrophobic and π-stacking contacts to DNA bases. This non-polar binding profile distinguishes resistomycin from classical Topo II inhibitors. In line with these predictions, resistomycin inhibited Topo II activity with an IC₅₀ of 21.48 nM, surpassing doxorubicin (30.16 nM). Cell-based assays further showed selective cytotoxicity across multiple cancer cell lines (IC₅₀ = 45.68–72.30 µM), while mechanistic studies in HCT-116 cells demonstrated dose-dependent apoptosis and G2/M cell cycle arrest. Collectively, these findings identify resistomycin as a potent DNA-intercalating Topo II inhibitor with a unique binding signature, supporting its potential as a scaffold for developing next-generation anticancer agents.
topoisomerase II inhibitorsDNA intercalationmolecular dockingmolecular dynamics simulation
Frontiers in Molecular Biosciences · مجلد 12 · 1621240-1621240
Background and aim: This study investigated the ameliorative effect of Silymarin-nanoliposome (SLNPs) against monosodium glutamate (MSG)-induced cerebellar toxicity, illuminating its impact on motor coordination. Methods: Forty male Wistar albino rats were divided into four groups. Group I (control group): rats received 2 mL of 0.9% NaCl solution; Group II (SLNPs group): rats received SLNPs with a dose of 500 μg/kg bw orally; Group III (MSG group): rats received 3.5 mg/kg bw of MSG intraperitoneally; and Group IV: rats received combined treatment of MSG + SLNPs for ten consecutive days. Results: MSG-induced cerebellar motor incoordination is represented by increased falls in rats and decreased tow latency spent on the rotarod test. Moreover, MSG altered cerebellar histological structure and significantly (p < 0.05) decreased antioxidant system activity and protein levels of phosphorylated phosphoinositide 3-kinases (p-PI3K), phosphorylated protein kinase B (p-AKT), and brain-derived neurotrophic factor (BDNF). Additionally, there is a decrease in the immunoexpression of nuclear factor erythroid 2-related factor 2 (Nrf2) and gene expression of heme oxygenase-1 (HO-1), tropomyosin receptor kinase B (TrkB), and anti-apoptotic B-cell lymphoma-2 (Bcl-2), alongside an increase in the sera and protein levels of proinflammatory cytokines tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-1 beta (IL-1β), immunoexpression of glial fibrillary acidic protein (GFAP), nuclear factor kabba beta (NF-κB), caspase-3, and gene expression of proapoptotic Bax. However, SLNPs prevented MSG-induced cerebellar toxicity, improving motor coordination and morphological structure by enhancing antioxidant, anti-inflammatory, and anti-apoptotic activity by stimulating the PI3K/AKT pathway. Conclusion: The current study indicated that SLNP administration protects against MSG-induced cerebellar damage, preventing cerebellar oxidative stress, inflammation, and apoptosis, opening the door to examining its clinical use in preventing MSG-induced cerebellar motor incoordination.